Today, Sarepta Therapeutics Inc. (SRPT) Given Hold Rating at SunTrust Banks Inc.

Today, Sarepta Therapeutics Inc. (SRPT) Given Hold Rating at SunTrust Banks Inc.

SunTrust Banks Inc. reissued their hold rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report issued on Monday morning. SunTrust Banks Inc. currently has a $52.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Oppenheimer Holdings Inc. upped their target price on shares of Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday, September 19th. Needham & Company LLC upped their target price on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a buy rating in a research report on Friday, July 22nd. Janney Montgomery Scott upgraded shares of Sarepta Therapeutics from a neutral rating to a buy rating and boosted their price target for the stock from $30.00 to $65.00 in a research note on Monday, September 19th. Piper Jaffray Cos. set a $68.00 price target on shares of Sarepta Therapeutics and gave the stock a buy rating in a research note on Tuesday, October 4th. Finally, Vetr upgraded shares of Sarepta Therapeutics from a sell rating to a hold rating and set a $17.28 price target on the stock in a research note on Monday, June 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $63.31.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.06% during mid-day trading on Monday, hitting $49.46. 383,066 shares of the stock were exchanged. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The company has a 50 day moving average of $45.66 and a 200 day moving average of $26.92. The firm’s market cap is $2.37 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the business earned ($0.87) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($4.23) earnings per share for the current fiscal year.

In related news, SVP David T. Howton sold 7,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $420,000.00. Following the completion of the sale, the senior vice president now owns 28,453 shares in the company, valued at approximately $1,707,180. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 40,179 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $2,410,740.00. Following the completion of the sale, the chief executive officer now directly owns 117,162 shares in the company, valued at $7,029,720. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas raised its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth about $211,000. BNP Paribas Arbitrage SA raised its stake in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the last quarter. Finally, National Planning Corp raised its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. 65.06% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Related posts

Leave a Comment